PLAU and neoplasm: We anticipate that anti-MSLN uCAR-like NK cells specifically accumulate in MSLN-positive tumor tissues, where the uCendR peptide is processed into active CendR peptides under the influence of uPA in the tumor microenvironment, triggering immune cells to penetrate deep into the tumor and enhancing the tumor-killing effects (Fig. 1).